Literature DB >> 18941232

Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis.

Cristina P Marques1, Maxim C-J Cheeran, Joseph M Palmquist, Shuxian Hu, Stina L Urban, James R Lokensgard.   

Abstract

Experimental murine herpes simplex virus (HSV)-1 brain infection stimulates microglial cell-driven proinflammatory chemokine production which precedes the presence of brain-infiltrating systemic immune cells. In the present study, we investigated the phenotypes and infiltration kinetics of leukocyte trafficking into HSV-infected murine brains. Using real-time bioluminescence imaging, the infiltration of luciferase-positive splenocytes, transferred via tail vein injection into the brains of HSV-infected animals, was followed over an 18-day time course. Flow cytometric analysis of brain-infiltrating leukocytes at 5, 8, 14, and 30 days postinfection (d.p.i.), was performed to assess their phenotype. A predominantly macrophage (CD45(high)CD11b(+)Ly6C(high)) and neutrophil (CD45(high)CD11b(+)Ly6G(+)) infiltration was seen early during infection, with elevated levels of TNF-alpha mRNA expression. By 14 d.p.i., the phenotypic profile shifted to a predominantly lymphocytic (CD45(high)CD3(+)) infiltrate. This lymphocyte infiltrate was detected until 30 d.p.i., when infectious virus could not be recovered, with CD8(+) and CD4(+) T cells present at a 3:1 ratio, respectively. This T lymphocyte infiltration paralleled increased IFN-gamma mRNA expression in the brain. Activation of resident microglia (CD45(int)CD11b(+)) was also detected until 30 d.p.i., as assessed by MHC class II expression. Activated microglial cells were further identified as the predominant source of IL-1beta. In addition, infected mice given primed immunocytes at 4 d.p.i. showed a significant increase in mortality. Taken together, these results demonstrate that intranasal infection results in early macrophage and neutrophil infiltration into the brain followed by prolonged microglial activation and T lymphocyte retention. Similar prolonged neuroimmune activation may contribute to the neuropathological sequelae observed in herpes encephalitis patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941232      PMCID: PMC2614272          DOI: 10.4049/jimmunol.181.9.6417

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers.

Authors:  M K Slifka; J L Whitton
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Role of viral persistence in retaining CD8(+) T cells within the central nervous system.

Authors:  N W Marten; S A Stohlman; C C Bergmann
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  CD8 T cells mediate transient herpes stromal keratitis in CD4-deficient mice.

Authors:  Andrew J Lepisto; Gregory M Frank; Min Xu; Patrick M Stuart; Robert L Hendricks
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

4.  Macrophage-depletion influences the course of murine HSV-1 keratitis.

Authors:  D Bauer; S Mrzyk; N van Rooijen; K P Steuhl; A Heiligenhaus
Journal:  Curr Eye Res       Date:  2000-01       Impact factor: 2.424

5.  Pathogenesis of herpes simplex hepatitis in macrophage-depleted mice: possible involvement of tumor necrosis factor-alpha and inducible nitric oxide synthase in massive apoptosis.

Authors:  Hiroshi Irie; Junji Shiga
Journal:  Anat Sci Int       Date:  2005-12       Impact factor: 1.741

6.  Role of macrophages in restricting herpes simplex virus type 1 growth after ocular infection.

Authors:  H Cheng; T M Tumpey; H F Staats; N van Rooijen; J E Oakes; R N Lausch
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-05       Impact factor: 4.799

7.  Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Authors:  Patric Lundberg; Paula V Welander; Carl K Edwards; Nico van Rooijen; Edouard Cantin
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

8.  Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice.

Authors:  Yan Sergerie; Guy Boivin; David Gosselin; Serge Rivest
Journal:  J Infect Dis       Date:  2007-02-07       Impact factor: 5.226

9.  The immune response to herpes simplex virus type 1 infection in susceptible mice is a major cause of central nervous system pathology resulting in fatal encephalitis.

Authors:  Patric Lundberg; Chandran Ramakrishna; Jeffrey Brown; J Michael Tyszka; Mark Hamamura; David R Hinton; Susan Kovats; Orhan Nalcioglu; Kenneth Weinberg; Harry Openshaw; Edouard M Cantin
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Dysregulated interferon-gamma responses during lethal cytomegalovirus brain infection of IL-10-deficient mice.

Authors:  Maxim C-J Cheeran; Shuxian Hu; Joseph M Palmquist; Thomas Bakken; Genya Gekker; James R Lokensgard
Journal:  Virus Res       Date:  2007-07-12       Impact factor: 3.303

View more
  82 in total

1.  The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.

Authors:  Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Min Wei; Yan Wang; Michal O Nowicki; Yoonhee P Ha; Stephen Bergin; Christine Hwang; Soledad A Fernandez; Balveen Kaur; Michael A Caligiuri; E Antonio Chiocca
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  IL-29/IL-28A suppress HSV-1 infection of human NT2-N neurons.

Authors:  Lin Zhou; Jieliang Li; Xu Wang; Li Ye; Wei Hou; Jie Ho; He Li; Wenzhe Ho
Journal:  J Neurovirol       Date:  2011-04-16       Impact factor: 2.643

3.  The case for immunomodulatory approaches in treating HSV encephalitis.

Authors:  Chandran Ramakrishna; Harry Openshaw; Edouard M Cantin
Journal:  Future Virol       Date:  2013-03-01       Impact factor: 1.831

4.  Resident T Cells Are Unable To Control Herpes Simplex Virus-1 Activity in the Brain Ependymal Region during Latency.

Authors:  Chandra M Menendez; Jeremy K Jinkins; Daniel J J Carr
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

5.  SOCS1/3 expression levels in HSV-1-infected, cytokine-polarized and -unpolarized macrophages.

Authors:  Adam Craig Reichard; Nagarjuna Reddy Cheemarla; Nancy Jane Bigley
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

6.  Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis.

Authors:  James R Lokensgard; Scott J Schachtele; Manohar B Mutnal; Wen S Sheng; Sujata Prasad; Shuxian Hu
Journal:  Glia       Date:  2015-06-04       Impact factor: 7.452

7.  Chronic cortical and subcortical pathology with associated neurological deficits ensuing experimental herpes encephalitis.

Authors:  Anibal G Armien; Shuxian Hu; Morgan R Little; Nicholas Robinson; James R Lokensgard; Walter C Low; Maxim C-J Cheeran
Journal:  Brain Pathol       Date:  2009-11-05       Impact factor: 6.508

8.  An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis.

Authors:  Olus Uyar; Nataly Laflamme; Jocelyne Piret; Marie-Christine Venable; Julie Carbonneau; Karima Zarrouk; Serge Rivest; Guy Boivin
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

Review 9.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

10.  Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells.

Authors:  Ana J Chucair-Elliott; Christopher Conrady; Min Zheng; Chandra M Kroll; Thomas E Lane; Daniel J J Carr
Journal:  Glia       Date:  2014-05-07       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.